Oncology Drug Applications Migrate As Part Of FDA's Reorganization Of OODP
Many NDAs, BLAs and INDs for cancer drugs are being reassigned to new review divisions as part of a reorganization of FDA’s Office of Oncology Drug Products.
Many NDAs, BLAs and INDs for cancer drugs are being reassigned to new review divisions as part of a reorganization of FDA’s Office of Oncology Drug Products.